1. Home
  2. CHSCO vs CMMB Comparison

CHSCO vs CMMB Comparison

Compare CHSCO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHSCO
  • CMMB
  • Stock Information
  • Founded
  • CHSCO N/A
  • CMMB 2004
  • Country
  • CHSCO United States
  • CMMB Israel
  • Employees
  • CHSCO N/A
  • CMMB N/A
  • Industry
  • CHSCO Farming/Seeds/Milling
  • CMMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • CHSCO Industrials
  • CMMB Health Care
  • Exchange
  • CHSCO Nasdaq
  • CMMB Nasdaq
  • Market Cap
  • CHSCO N/A
  • CMMB 37.3M
  • IPO Year
  • CHSCO N/A
  • CMMB N/A
  • Fundamental
  • Price
  • CHSCO $26.62
  • CMMB $1.96
  • Analyst Decision
  • CHSCO
  • CMMB Strong Buy
  • Analyst Count
  • CHSCO 0
  • CMMB 2
  • Target Price
  • CHSCO N/A
  • CMMB $7.50
  • AVG Volume (30 Days)
  • CHSCO N/A
  • CMMB 77.2K
  • Earning Date
  • CHSCO N/A
  • CMMB 03-06-2025
  • Dividend Yield
  • CHSCO N/A
  • CMMB N/A
  • EPS Growth
  • CHSCO N/A
  • CMMB N/A
  • EPS
  • CHSCO N/A
  • CMMB N/A
  • Revenue
  • CHSCO N/A
  • CMMB N/A
  • Revenue This Year
  • CHSCO N/A
  • CMMB N/A
  • Revenue Next Year
  • CHSCO N/A
  • CMMB N/A
  • P/E Ratio
  • CHSCO N/A
  • CMMB N/A
  • Revenue Growth
  • CHSCO N/A
  • CMMB N/A
  • 52 Week Low
  • CHSCO N/A
  • CMMB $0.55
  • 52 Week High
  • CHSCO N/A
  • CMMB $2.55
  • Technical
  • Relative Strength Index (RSI)
  • CHSCO 52.86
  • CMMB 46.64
  • Support Level
  • CHSCO $26.19
  • CMMB $1.86
  • Resistance Level
  • CHSCO $26.75
  • CMMB $2.06
  • Average True Range (ATR)
  • CHSCO 0.23
  • CMMB 0.14
  • MACD
  • CHSCO 0.01
  • CMMB -0.02
  • Stochastic Oscillator
  • CHSCO 67.19
  • CMMB 30.30

About CHSCO CHS Inc. Class B Cumulative Redeemable Preferred Stock

CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Share on Social Networks: